HG

Hy-Gro Chemicals Pharmtek Pvt. Ltd.

Legacy profile
Business Type Manufacturer
Products / Services Dextropropoxyphene hcl, dextropropoxyphene napsylate, citalopram hbr, mesalazine (5-amino salicylic acid), parathiazine theoclate, clopidogrel bisulphate, paroxetine, d-oxyphene, citadiol
Quick answer

Hy-Gro Chemicals Pharmtek Pvt. Ltd. is a Manufacturer. Main products and services: Dextropropoxyphene hcl, dextropropoxyphene napsylate, citalopram hbr, mesalazine (5-amino salicylic acid), parathiazine ….

Company Profile

Hy-Gro Chemicals Pharmtek Pvt. Ltd. (Hy-Gro) is engaged in the manufacture of Advanced Intermediates, Active Pharmaceutical Ingredients (APIs), and Finished Dosages.

Hy-Gro was established in early 1970's as a trading company and ventured into the manufacture of bulk drugs in an associate company in 1980. In 1995, Hy-Gro set up its own manufacturing facility in Bollaram, India. This facility is ISO 9001-2000 and WHO-GMP compliant manufacturing Active Pharmaceutical Ingredients (APIs) and Drug Intermediates for both the domestic and international markets.

We are currently marketing our APIs and Drug Intermediates in 11 countries across the globe. Our customers include pharmaceutical majors in the regulated markets of Europe and the US.

Critical to our growth strategy is a strong emphasis towards Research and Development, an area in which we have invested heavily over the last 5 years. We have a well-staffed R & D laboratory outfitted with the latest equipment including a state-of-the-art pilot plant capable of handling scale-up operations.

In 2002, Hy-Gro ventured into the manufacture of Pharmaceutical Formulations, setting up a new unit in its Bollaram facility. This unit is GMP approved and is currently catering to the domestic market. Our products include Analgesics, Anti Inflammatory, Anti Bacterial and Anti Ulcerants among others.

Hygro is committed towards Quality, Safety, Environment and Health. The unit has been approved by multinational pharmaceutical companies and we are currently in the process of setting up an USFDA compliant API Production facility and Finished Dosages (Tablets and Capsules) facility. The API facility is expected to be completed by December 2005 and the Finished Dosages facility by December 2006.

Business Categories

Similar suppliers in Chemicals